Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma

SHANGHAI, China, April 27, 2023 -- Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of... | April 27, 2023

Related Keywords

Peking ,Beijing ,China ,Suzhou ,Jiangsu ,United States ,Guangzhou ,Guangdong ,Maryland ,Shanghai ,United Kingdom ,Jianjun ,Shaanxi ,Uzbekistan ,Renji ,Henan ,San Francisco ,California ,Chinese ,Zhi Li ,Junshi Bioscience ,Junshi Biosciences ,Radiographic Review Committee ,Shanghai Junshi Biosciences Co Ltd ,Ir Team ,University Cancer Hospital ,Drug Administration ,Regulatory Agency ,International Metastatic Renal Cell Carcinoma Database Consortium ,Data Monitoring Committee ,Pr Team ,National Reimbursement Drug List ,Global Research ,European Medicines Agency ,Independent Data Monitoring Committee ,Chinese Medical Journal ,Development President ,Independent Radiographic Review Committee ,Professor Jun ,Peking University Cancer Hospital ,Professor Yiran ,Renji Hospital ,Shanghai Jiao Tong University School ,Southeast Asia ,Biologics License Application ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,Emergency Use Authorizations ,Shanghai Junshi Biosciences Co ,Td Stock Exchange ,News ,Information ,Press Release ,Pril ,023 ,Junshi ,Iosciences ,Td ,Reading ,Iopharmaceutical ,Company ,Edicated ,O ,The ,End ,Ommercialization 1877 Cne100003ff7 ,